8 papers in the library · 56 citations · publishing 2023-2026
Curr Psychiatry Rep June 5, 2026 Matthew J Reid, Hannes Kettner, Tessa F. Blanken et al. correction
Correction to: Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.
SLEEPJ May 1, 2026 Matthew J. Reid, E. Weisman, Luis Luna Martinez et al.
Despite evidence of an acute effect of psilocybin on sleep physiology, its enduring effects beyond the period of acute administration and active metabolism remain unexplored. Within a clinical trial of psilocybin-assisted therapy for alcohol use disorder comorbid with major depressive disorder, we monitored sleep for ten continuous nights (3 pre-dose | 7 post-dose) in participants (N=22)...
SLEEPJ May 1, 2026 Matthew J. Reid, Abigail Yaffe, Ian Geithner et al.
Post-treatment Lyme Disease (PTLD) is a post-infectious syndrome characterized by fatigue, hypersomnia, sleep-disturbance, musculoskeletal pain and/or cognitive difficulties. As part of an open-label pilot study of psilocybin-assisted treatment for PTLD, we explored potential for psilocybin-assisted treatment to remedy sleep-related disturbances in this population. 12 participants consented to...
Journal of psychopharmacology (Oxford, England) February 5, 2026 Benjamin R. Lewis, Matthew J Reid, Andrew M Novick et al.
Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown significant promise for the treatment of mental health conditions in recent clinical trials. Organizations such as the National Network of Depression Centers (NNDCs) can play a pivotal role in uniting researchers and clinicians working in this field...
EClinicalMedicine September 24, 2025 Megan Hosein, Matthew J Reid, Sarah A. Walser et al. 5 citations
The potential for psilocybin, and other psychedelic drugs, to fulfil a much needed and potentially transformative class of psychiatric treatments has garnered significant attention. Consequently, there has been a great deal of interest and investment in accelerating its development and potential implementation in routine clinical practice. However, the expanding scope of scientific discovery,...
Current Psychiatry Reports November 1, 2024 Matthew J Reid, Hannes Kettner, Tessa F. Blanken et al. 4 citations
Abstract Purpose of the study Psilocybin is a rapidly-emerging treatment for depression, yet its impact on sleep is not well understood. We sought to explore the literature on sleep and psilocybin use, and explore the topic using our own primary data. Findings Whilst clinical trials demonstrate large depressive symptom improvements, the impact of psilocybin on sleep quality or insomnia...
The lancet. Psychiatry October 1, 2023 Gustavo C Medeiros, Malcolm Matheson, Isabella Demo et al. 38 citations
Ketamine is an effective antidepressant, but there is substantial variability in patient response and the precise mechanism of action is unclear. Neuroimaging can provide predictive and mechanistic insights, but findings are limited by small sample sizes. This systematic review covers neuroimaging studies investigating baseline (pre-treatment) and longitudinal (post-treatment) biomarkers of...
Mindfulness April 1, 2023 Carly Hunt, Janelle E. Letzen, Samuel R Krimmel et al. 9 citations
Mindfulness-based interventions (MBIs) have emerged as promising prophylactic episodic migraine treatments. The present study investigated biopsychosocial predictors and outcomes associated with formal, daily-life meditation practice in migraine patients undergoing MBI, and whether augmented mindfulness mechanistically underlies change. Secondary analyses of clinical trial data comparing a...